Delaware (State or other jurisdiction of incorporation or organization)

13-3986004 (I.R.S.  Employer Identification No.)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	SSKN	The NASDAQ Stock Market LLC

	Large accelerated filer [  ]		Accelerated filer [  ]
	Non-accelerated filer [x]		Smaller reporting company [x]
	Emerging growth company [  ]

Part I. Financial Information:			PAGE
	ITEM 1.  Financial Statements:
	a.	Condensed Consolidated Balance Sheets as of June 30, 2020 (unaudited) and December 31, 2019	1
	b.	Condensed Consolidated Statements of Operations for the three months ended June 30, 2020 and, 2019 (unaudited)	2
	c.	Condensed Consolidated Statements of Operations for the six months ended June 30, 2020 and, 2019 (unaudited)	3
	d.	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the six months ended June 30, 2019 (unaudited)	4
	e.	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the six months ended June 30, 2020	5
	f.	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and, 2019 (unaudited)	6
	g.	Notes to Unaudited Condensed Consolidated Financial Statements	7
	ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations		23
	ITEM 3.  Quantitative and Qualitative Disclosure about Market Risk		32
	ITEM 4.  Controls and Procedures		32
Part II. Other Information:
	ITEM 1.  Legal Proceedings		33
	ITEM 1A.  Risk Factors		33
	ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds		33
	ITEM 3.  Defaults Upon Senior Securities		33
	ITEM 4.  Mine Safety Disclosures		33
	ITEM 5.  Other Information		33
	ITEM 6.  Exhibits		33
		Signatures	34
		Certifications	E-31.1

		June 30, 2020				December 31, 2019
ASSETS		(unaudited)
Current assets:
Cash and cash equivalents		$	11,231			$	8,129
Restricted cash			7,397				7,500
Accounts receivable, net of allowance for doubtful accounts of $256 and $184, respectively			1,361				4,386
Inventories			3,470				3,027
Prepaid expenses and other current assets			430				513
Total current assets			23,889				23,555
Property and equipment, net			4,999				5,369
Operating lease right-of-use assets, net			1,155				1,314
Intangible assets, net			7,050				7,955
Goodwill			8,803				8,803
Other assets			314				347
Total assets		$	46,210			$	47,343
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Note payable		$	7,275			$	7,275
Current portion of long-term debt			799				-
Accounts payable			2,451				1,880
Other accrued liabilities			4,703				5,134
Current portion of operating lease liabilities			353				313
Deferred revenues			1,020				2,832
Total current liabilities			16,601				17,434
Long-term liabilities:
Long-term debt, net			1,729				-
Deferred tax liability			135				-
Long-term operating lease liabilities, net			896				1,078
Other liabilities			71				178
Total liabilities			19,432				18,690
Commitments and contingencies (see Note 15)
Stockholders' equity:
Series C Convertible Preferred Stock, $.10 par value, 10,000,000 shares authorized; - and 2,103 shares issued and outstanding at June 30, 2020 and, December 31, 2019, respectively			-				1
Common Stock, $.001 par value, 150,000,000 shares authorized; 33,754,909  and 32,932,273  shares issued and outstanding at June 30, 2020 and, December 31, 2019, respectively			34				33
Additional paid-in capital			244,020				243,180
Accumulated deficit			(217,276	)			(214,561	)
Total stockholders' equity			26,778				28,653
Total liabilities and stockholders’ equity		$	46,210			$	47,343

		For the Three Months Ended June 30,
		2020				2019
Revenues, net		$	4,030			$	7,725
Cost of revenues			2,066				2,815
Gross profit			1,964				4,910
Operating expenses:
Engineering and product development			247				235
Selling and marketing			1,442				2,958
General and administrative			1,890				2,700
			3,579				5,893
Loss from operations			(1,615	)			(983	)
Other expense, net:
Interest expense, net			(18	)			(145	)
			(18	)			(145	)
Loss before income taxes			(1,633	)			(1,128	)
Income tax (expense) benefit			(47	)			46
Net loss		$	(1,680	)		$	(1,082	)
Loss attributable to common shares		$	(1,680	)		$	(1,007	)
Loss attributable to Series C Convertible Preferred shares			-			$	(75	)
Loss per common share:
Basic		$	(0.05	)		$	(0.03	)
Diluted		$	(0.05	)		$	(0.03	)
Shares used in computing loss per common share:
Basic			33,731,739				31,359,104
Diluted			33,731,739				31,359,104
Loss per Series C Convertible Preferred share basic and diluted			-			$	(11.94	)
Shares used in computing loss per basic and diluted Series C Convertible Preferred shares			-				6,250

		For the Six Months Ended June 30,
		2020				2019
Revenues, net		$	10,760			$	15,208
Cost of revenues			4,397				5,689
Gross profit			6,363				9,519
Operating expenses:
Engineering and product development			539				539
Selling and marketing			4,395				6,024
General and administrative			3,992				5,180
			8,926				11,743
Loss from operations			(2,563	)			(2,224	)
Other expense, net:
Interest expense, net			(17	)			(280	)
			(17	)			(280	)
Loss before income taxes			(2,580	)			(2,504	)
Income tax (expense) benefit			(135	)			89
Net loss		$	(2,715	)		$	(2,415	)
Loss attributable to common shares		$	(2,693	)		$	(2,226	)
Loss attributable to Series C Convertible Preferred shares		$	(22	)		$	(189	)
Loss per common share:
Basic		$	(0.08	)		$	(0.07	)
Diluted		$	(0.08	)		$	(0.07	)
Shares used in computing loss per common share:
Basic			33,448,030				31,033,114
Diluted			33,448,030				31,033,114
Loss per Series C Convertible Preferred share basic and diluted		$	(29.93	)		$	(26.66	)
Shares used in computing loss per basic and diluted Series C Convertible Preferred shares			740				7,093

		Convertible Preferred Stock – Series C								Common Stock								Additional Paid-In				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
BALANCE, January 1, 2019			9,968			$	1				29,943,086			$	30			$	241,988			$	(210,771	)		$	31,248
Stock-based compensation			-				-				-				-				323				-				323
Conversion of convertible preferred stock into common stock			(3,090	)			-				1,148,698				1				(1	)			-				-
Exercise of stock options			-				-				28,824				-				-				-				-
Net loss			-				-				-				-				-				(1,333	)			(1,333	)
BALANCE, March 31, 2019			6,878			$	1				31,120,608			$	31			$	242,310			$	(212,104	)		$	30,238

Conversion of convertible preferred stock into common stock			(4,775	)			-				1,775,093				2				(2	)			-				-
Stock-based compensation			-				-				-				-				303				-				303
Exercise of stock options			-				-				7,586				-				-
Net loss			-				-				-				-				-				(1,082	)			(1,082	)
BALANCE, June 30, 2019			2,103			$	1				32,903,287			$	33			$	242,611			$	(213,186	)		$	29,459

		Convertible Preferred Stock – Series C								Common Stock								Additional Paid-In				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
BALANCE, January 1, 2020			2,103			$	1				32,932,273			$	33			$	243,180			$	(214,561	)		$	28,653
Stock-based compensation			-				-				-				-				430				-				430
Conversion of convertible preferred stock into common stock			(2,103	)			(1	)			782,089				1												-
Net loss			-				-				-				-				-				(1,035	)			(1,035	)
BALANCE, March 31, 2020			-			$	-				33,714,362			$	34			$	243,610			$	(215,596	)		$	28,048
Stock-based compensation			-				-								-				410				-				410
Issuance of restricted stock			-				-				40,547				-												-
Net loss			-				-																(1,680	)			(1,680	)
BALANCE, June 30, 2020			-			$	-				33,754,909			$	34			$	244,020			$	(217,276	)		$	26,778

		For the Six Months Ended June 30,
		2020				2019
Cash Flows From Operating Activities:
Net loss		$	(2,715	)		$	(2,415	)
Adjustments to reconcile net loss to net cash provided by  operating activities:
Depreciation and amortization			1,986				2,347
Amortization of right-of-use asset			159				147
Provision for doubtful accounts			72				2
Loss on disposal of property and equipment and lasers placed in service			19				22
Stock-based compensation			840				626
Deferred taxes			135				(89	)
Amortization of debt discount			-				12
Amortization of deferred financing costs			-				57
Changes in operating assets and liabilities:
Accounts receivable			2,953				(85	)
Inventories			(443	)			(813	)
Prepaid expenses and other assets			116				(42	)
Accounts payable			571				327
Other accrued liabilities			(431	)			248
Other liabilities			(107	)			(5	)
Operating lease liabilities			(142	)			(126	)
Deferred revenues			(1,812	)			193
Net cash provided by operating activities			1,201				406
Cash Flows From Investing Activities:
Lasers placed-in-service			(730	)			(947	)
Purchases of property and equipment			-				(5	)
Net cash used in investing activities			(730	)			(952	)
Cash Flows From Financing Activities:
Proceeds from note payable and long-term debt			2,528				-
Net cash provided by financing activities			2,528				-
Net increase (decrease) in cash and cash equivalents and restricted  cash			2,999				(546	)
Cash, cash equivalents and restricted cash, beginning of period			15,629				16,487
Cash, cash equivalents and restricted cash, end of period		$	18,628			$	15,941
Cash and cash equivalents		$	11,231			$	15,941
Restricted cash			7,397				-
		$	18,628			$	15,941
Supplemental information of cash and non-cash transactions:
Cash paid for interest		$	103			$	404
Lease liabilities arising from obtaining right-of-use assets		$	-			$	1,632

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.

		Three Months Ended June 30, 2020								Six Months Ended June 30, 2020
		Common Stock				Series C Convertible Preferred Stock				Common Stock				Series C Convertible Preferred Stock
Loss attributable to each class		$	(1,680	)			-			$	(2,693	)		$	(22	)
Weighted average number of shares outstanding during the period			33,731,739				-				33,448,030				740
Basic and Diluted loss per share		$	(0.05	)			-			$	(0.08	)		$	(29.93	)

		Three Months Ended June 30, 2019								Six Months Ended June 30, 2019
		Common Stock				Series C Convertible Preferred Stock				Common Stock				Series C Convertible Preferred Stock
Loss attributable to each class		$	(1,007	)		$	(75	)		$	(2,226	)		$	(189	)
Weighted average number of shares outstanding during the period			31,359,104				6,250				31,033,114				7,093
Basic and Diluted loss per share		$	(0.03	)		$	(11.94	)		$	(0.07	)		$	(26.66	)

		Three Months Ended June 30,				Six Months Ended June 30,
		2020		2019		2020		2019
Common stock purchase warrants		697,154		2,034,882		723,527		2,133,489
Restricted stock units		151,646		120,773		160,334		125,150
Common stock options		4,908,038		4,184,193		4,908,038		4,252,682
Total		5,756,838		6,339,848		5,791,899		6,511,321

		Three Months Ended June 30, 2020
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	2,670			$	125			$	2,795
Foreign			126				1,109				1,235
Total		$	2,796			$	1,234			$	4,030

		Six Months Ended June 30, 2020
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	8,267			$	440			$	8,707
Foreign			230				1,823				2,053
Total		$	8,497			$	2,263			$	10,760

		Three Months Ended June 30, 2019
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	5,839			$	378			$	6,217
Foreign			-				1,508				1,508
Total		$	5,839			$	1,886			$	7,725

		Six Months Ended June 30, 2019
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	11,151			$	702			$	11,853
Foreign			-				3,355				3,355
Total		$	11,151			$	4,057			$	15,208

Remaining 2020		$	244
2021			474
2022			474
2023			405
2024			178
Thereafter			-
Total		$	1,775

		June 30, 2020				December 31, 2019
Raw materials and work-in-process		$	2,756			$	2,651
Finished goods			714				376
Total inventories		$	3,470			$	3,027

		June 30, 2020				December 31, 2019
Lasers placed-in-service		$	21,553			$	20,925
Equipment, computer hardware and software			146				146
Furniture and fixtures			234				234
Leasehold improvements			26				26
			21,959				21,331
Accumulated depreciation and amortization			(16,960	)			(15,962	)
Property and equipment, net		$	4,999			$	5,369

		Balance				Accumulated Amortization				Intangible assets, net
Core technology		$	5,700			$	(2,850	)		$	2,850
Product technology			2,000				(2,000	)			-
Customer relationships			6,900				(3,450	)			3,450
Tradenames			1,500				(750	)			750
		$	16,100			$	(9,050	)		$	7,050

Remaining 2020		$	705
2021			1,410
2022			1,410
2023			1,410
2024			1,410
2025			705
Total		$	7,050

		June 30, 2020				December 31, 2019
Accrued warranty, current		$	119			$	170
Accrued compensation, including commissions and vacation			1,000				1,193
Accrued state sales, use and other taxes			3,097				3,193
Accrued professional fees and other accrued liabilities			487				578
Total other accrued liabilities		$	4,703			$	5,134

		Three Months Ended, June 30,								Six Months Ended, June 30,
		2020				2019				2020				2019
Accrual at beginning of period		$	181			$	272			$	232			$	238
Additions charged to warranty expense			6				75				9				143
Expiring warranties/claimed satisfied			(48	)			(56	)			(102	)			(90	)
Total			139				291				139				291
Less: current portion			(119	)			(194	)			(119	)			(194	)
Total long-term accrued warranty costs		$	20			$	97			$	20			$	97

		June 30, 2020
Term notes		$	2,528
Less: current portion			(799	)
Total long-term debt		$	1,729

Issue Date	Expiration Date		Total Warrants				Exercise Price
December 30, 2015	December 30, 2020			130,089			$	5.65
January 29, 2016	January 29, 2021			19,812			$	5.30
				149,901

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	2,796			$	1,234			$	4,030
Costs of revenues			1,364				702				2,066
Gross profit			1,432				532				1,964
Gross profit %			51.2	%			43.1	%			48.7	%
Allocated operating expenses:
Engineering and product development			225				22				247
Selling and marketing			1,341				101				1,442
Unallocated operating expenses			-				-				1,890
			1,566				123				3,579
Income (loss) from operations			(134	)			409				(1,615	)
Interest income, net			-				-				(18	)
Income (loss) before income taxes		$	(134	)		$	409			$	(1,633	)

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	8,497			$	2,263			$	10,760
Costs of revenues			3,166				1,231				4,397
Gross profit			5,331				1,032				6,363
Gross profit %			62.7	%			45.6	%			59.1	%
Allocated operating expenses:
Engineering and product development			499				40				539
Selling and marketing			4,138				257				4,395
Unallocated operating expenses			-				-				3,992
			4,637				297				8,926
Income (loss) from operations			694				735				(2,563	)
Interest income, net			-				-				(17	)
Income (loss) before income taxes		$	694			$	735			$	(2,580	)

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	5,839			$	1,886			$	7,725
Costs of revenues			1,733				1,082				2,815
Gross profit			4,106				804				4,910
Gross profit %			70.3	%			42.6	%			63.6	%
Allocated operating expenses:
Engineering and product development			198				37				235
Selling and marketing			2,771				187				2,958
Unallocated operating expenses			-				-				2,700
			2,969				224				5,893
Income (loss) from operations			1,137				580				(983	)
Interest expense, net			-				-				(145	)
Income (loss) before income taxes		$	1,137			$	580			$	(1,128	)

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	11,151			$	4,057			$	15,208
Costs of revenues			3,526				2,163				5,689
Gross profit			7,625				1,894				9,519
Gross profit %			68.4	%			46.7	%			62.6	%
Allocated operating expenses:
Engineering and product development			440				99				539
Selling and marketing			5,539				485				6,024
Unallocated operating expenses			-				-				5,180
			5,979				584				11,743
Income (loss) from operations			1,646				1,310				(2,224	)
Interest expense, net			-				-				(280	)
Income (loss) before income taxes		$	1,646			$	1,310			$	(2,504	)

For the year ending December 31,		Amount
Remaining 2020		$	228
2021			456
2022			371
2023			242
2024			186
Total remaining lease payments			1,483
Less: imputed interest			(234	)
Total lease liabilities		$	1,249

	•	XTRAC® Excimer Laser. XTRAC received FDA clearance in 2000 and has since become a widely recognized treatment among dermatologists for psoriasis and other skin diseases. The XTRAC System delivers ultra-narrowband ultraviolet B (“UVB”) light to affected areas of skin. Following a series of treatments typically performed twice weekly, psoriasis remission can be achieved, and vitiligo patches can be re-pigmented. XTRAC is endorsed by the National Psoriasis Foundation, and its use for psoriasis is covered by nearly all major insurance companies, including Medicare. We estimate that more than half of all major insurance companies now offer reimbursement for vitiligo as well, a figure that is increasing.
	•	In the third quarter of 2018, we announced the FDA granted clearance for our Multi Micro Dose (MMD) tip for our XTRAC excimer laser. The MMD Tip accessory is indicated for use in conjunction with the XTRAC laser system to filter the Narrow Band UVB (“NB-UVB”) light at delivery in order to calculate and individualize the maximum non-blistering dose for a particular patient.
	•	In the third quarter of 2018, we announced the launch of our S3®, the next generation XTRAC. The S3 is smaller, faster and has a smart user interface.
	•	In January 2020, we announced the FDA granted clearance of our XTRAC Momentum Excimer Laser Platform.
	•	VTRAC® Lamp. VTRAC received FDA clearance in 2005 and provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2020				2019				2020				2019
Dermatology Recurring Procedures		$	2,796			$	5,839			$	8,497			$	11,151
Dermatology Procedures Equipment			1,234				1,886				2,263				4,057
Total Revenues		$	4,030			$	7,725			$	10,760			$	15,208

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2020				2019				2020				2019
Dermatology Recurring Procedures		$	1,364			$	1,733				3,166			$	3,526
Dermatology Procedures Equipment			702				1,082				1,231				2,163
Total Cost of Revenues		$	2,066			$	2,815			$	4,397			$	5,689

Company Profit Analysis		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2020				2019				2020				2019
Revenues		$	4,030			$	7,725			$	10,760			$	15,208
Percent decrease			(47.8	)%							(29.2	)%
Cost of revenues			2,066				2,815				4,397				5,689
Percent decrease			(26.6	)%							(22.7	)%
Gross profit		$	1,964			$	4,910			$	6,363			$	9,519
Gross profit  percentage			48.7	%			63.6	%			59.1	%			62.6	%

Dermatology Recurring Procedures		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2020				2019				2020				2019
Revenues		$	2,796			$	5,839			$	8,497			$	11,151
Percent decrease			(52.1	)%							(23.8	)%
Cost of revenues			1,364				1,733				3,166				3,526
Percent decrease			(21.3	)%							(10.2	)%
Gross profit		$	1,432			$	4,106			$	5,331			$	7,625
Gross profit  percentage			51.2	%			70.3	%			62.7	%			68.4	%

Dermatology Procedures Equipment		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2020				2019				2020				2019
Revenues		$	1,234			$	1,886			$	2,263			$	4,057
Percent decrease			(34.6	)%							(44.2	)%
Cost of revenues			702				1,082				1,231				2,163
Percent decrease			(35.1	)%							(43.1	)%
Gross profit		$	532			$	804			$	1,032			$	1,894
Gross profit  percentage			43.1	%			42.6	%			45.6	%			46.7	%

		For the Three Months Ended June 30,								For the Six Months Ended June 30
		2020				2019				2020				2019
Net Loss		$	(1,680	)		$	(1,082	)		$	(2,715	)		$	(2,415	)
Adjustments:
Depreciation/amortization*			1,028				1,197				2,145				2,494
Income taxes			47				(46	)			135				(89	)
Interest expense, net			18				145				17				280
Non-GAAP EBITDA			(587	)			214				(418	)			270
Stock compensation			410				303				840				626
Non-GAAP adjusted EBITDA		$	(177	)		$	517			$	422			$	896

•	forecasts of future business performance, consumer trends and macro-economic conditions, including the timing and pace of physician practices opening back up and remaining open after the COVID-19 pandemic subsides and/or regional, statewide, or country-wide restrictions are re-imposed, and our ability and its effectiveness to stimulate recurring revenue by generating patient referrals to our provider customers
•	descriptions of market and/or competitive conditions;
•	descriptions of plans or objectives of management for future operations, products or services;
•	our estimates regarding the sufficiency of our cash resources, expenses, capital requirements and needs for additional financing, compliance with the terms of the PPP loan and related regulations, the terms of the EIDL loan and our ability to obtain additional financing;
•	our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;
•	our ability to obtain and maintain regulatory approvals of our products;
•	anticipated results of existing or future litigation;
•	health emergencies, the spread of infectious diseases; and
•	descriptions or assumptions underlying or related to any of the above items.

3.1		Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Registration Statement on Form S-3 (File No. 333-167113), as filed on May 26, 2010).
3.2		Fourth Amended and Restated Bylaws of the Company (Incorporated by reference to Exhibit 3.2 contained in our Form 8-K current report as filed on January 8, 2016).
3.3		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2013 filed on August 7, 2013).
3.4		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on July 10, 2014).

3.5		Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on February 3, 2014).
3.6		Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on July 23, 2014).
3.7		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, as filed on September 30, 2015).
3.8		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, as filed on January 8, 2016).
3.9		Certificate of Designations of Series C Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, as filed on September 25, 2017).
10.1		Paycheck Protection Program Term Note, Disbursement Request & Authorization, and Errors and Omissions Agreement dated April 22, 2020 (incorporated by reference to Exhibit 10.1 contained in our Current Report on Form 8-K, as filed on April 27, 2020).
10.2		U.S. Small Business Administration Loan Authorization and Agreement, dated as of March 26, 2020 and executed May 22, 2020, between the SBA and the Company (incorporated by reference to Exhibit 10.1 contained in our Current Report on Form 8-K, as filed on May 26, 2020.
10.3		U.S. Small Business Administration Note (Secured Disaster Loans), dated as of March 26, 2020 and executed May 22, 2020, by the Company for the benefit of the SBA (incorporated by reference to Exhibit 10.2 contained in our Current Report on Form 8-K, as filed on May 26, 2020)
10.4		U.S. Small Business Administration Security Agreement dated as of March 26, 2020 and executed May 22, 2020, between the SBA and the Company (incorporated by reference to Exhibit 10.3 contained in our Current Report on Form 8-K, as filed on May 26, 2020).

31.1		Rule 13a-14(a) Certificate of Chief Executive Officer
31.2		Rule 13a-14(a) Certificate of Chief Financial Officer
32.1*		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Schema
101.CAL		XBRL Taxonomy Calculation Linkbase
101.DEF		XBRL Taxonomy Definition Linkbase
101.LAB		XBRL Taxonomy Label Linkbase
101.PRE		XBRL Taxonomy Presentation Linkbase

*

The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

STRATA SKIN SCIENCES, INC.

Date   August 12, 2020	By:	/s/ Dolev Rafaeli
		Name  Dolev Rafaeli
		Title    President & Chief Executive Officer

Date   August 12, 2020	By:	/s/ Matthew C. Hill
		Name  Matthew C. Hill
		Title    Chief Financial Officer